Healthcare Review: Pluristem Therapeutics, Vanda Pharmaceuticals, VIVUS, Protalix BioTherapeutics, Keryx Biopharmaceuticals Print E-mail
By Staff and Wire Reports   
Wednesday, 19 June 2013 14:47
U.S. stocks fell on Wednesday, with the losses accelerating even after the Federal Reserve said it would hold steady with its monetary policy. The central bank gave no explicit indication that it was close to pulling back on its program to buy $85 billion in bonds per month, a policy that has been a key to the market's rally this year. Investors have speculated the Fed might start drawing down soon, contributing to a spate of volatility, though equities advanced strongly on both Monday and Tuesday ahead of the statement. Following are notable movers:-

Pluristem Therapeutics Inc. (NASDAQ:PSTI) stock is trading at $2.79. The company on June 19 provided an update on the status of its clinical trials in Intermittent Claudication (IC). As previously announced, on June 4, 2013 the company received notification from the U.S. Food & Drug Administration (FDA) that its U.S. phase II IC trial was put on hold following the hospitalization of a patient with an allergic reaction in the company's IC trial in the United States.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares dropped 18.96% to $8.86. The company on June 17 presented additional data at ENDO 2013, the Endocrine Society's 95(th) Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms. This effect further confirms tasimelteon's potential to reset the master body clock and address the circadian desynchrony which is inherent in Non-24-Hour Disorder (Non-24).

The SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies were designed to assess the safety, efficacy and maintenance effect of tasimelteon for Non-24. Currently there is no approved FDA treatment for Non-24.

VIVUS, Inc. (NASDAQ:VVUS) shares gained 1.09% to $13.91. The company on June 19 announced positive results from a multicenter, placebo-controlled study, TA-501, designed to assess the efficacy of STENDRA™ (avanafil) in approximately 15 minutes. In the study, STENDRA patients achieved statistically significant improvement over placebo, in the mean proportion of attempts that resulted in erections sufficient for successful intercourse, as early as 10 minutes for the 200 mg dose and 12 minutes for the 100 mg dose after being taken.

Protalix BioTherapeutics Inc. (NYSEMKT:PLX) shares gained 2.17% to $5.19 in the morning hour. The company on June 19 announced that it has entered into a supply and technology transfer agreement with Fundação Oswaldo Cruz (commonly referred to as Fiocruz), an arm of the Brazilian Ministry of Health for UPLYSO™ (alfataliglicerase), the Company's proprietary enzyme replacement therapy for the treatment of Gaucher disease. Gaucher disease is a rare lysosomal storage disorder that affects approximately 10,000 people worldwide.

Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 8.73% to $8.33. J.P. Morgan analyst Cory Kasimov initiated coverage on Keryx Biopharmaceuticals on June 19 with a rating of Overweight and a price target of $13.

Additionally, the company on June 3 announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter